Pharma & Biotech

Chronic diseases like dementia, COPD, rheumatoid arthritis or diabetes are complex, with multiple genetic, metabolic and epidemiological factors acting together. Existing genetic analysis approaches only scratch the surface of their varied biology.

PrecisionLife’s powerful combinatorial analysis platform reveals deep new insights into how different factors drive disease in different patient sub-groups. We use this to identify drugable targets addressing clinically relevant pockets of unmet medical need in common diseases.

At PrecisionLife we believe that developing successful medicines depends on picking the right target, based on understanding the range of disease biology across your patient population. We couple our unique target discovery platform with the proven 5Rs discovery framework, and extend it to include selection of targets with the right efficacy potential in order to minimize efficacy risks in later clinical trial phases.

INDx indication extension is precision repositioning with companion patient stratification biomarkers for a faster, cheaper and derisked route to the approval of new therapies to address unmet medical needs and achieve higher returns on R&D investment.

PrecisionLife combinatorial analytics generates more insights into disease biology than any other method. This enables us to perform high-resolution patient stratification for an accurate and scalable route to mapping existing drugs and drug candidates to patient subgroups in new disease indications – finding you high-value commercial opportunities, aligned to your strategic therapeutic areas, with high efficacy prediction scores and faster routes to market.

PrecisionLife delivers innovative options for addressing unmet medical needs and valuable insights into the biology of complex, chronic diseases, including:

• High resolution patient stratification showing clinically relevant sub-groups of patients with unmet clinical need – see our Non-T2 asthma disease study.
• Novel validated drug targets with tool compounds and full 5Rs data packages that are mapped to patient sub-groups and cellular mechanisms implicated in disease – see our ALS disease study.
• Patient stratification biomarkers that can be used to plan future inclusion/exclusion criteria for clinical trials – see our Non-T2 asthma disease study.
• Combinatorial Risk Scores – which have theranostic potential and describe individual disease risk and trajectories – see our Type-II diabetes complications study.